We need novel approaches to trial design to address challenges posed by emerging infectious diseases, rare diseases, and new cancer subtypes defined by genetic criteria. By designing trials with adaptive features tailored to specific situations and needs, CDER statisticians are helping to make clinical evaluation of new treatments for these diseases more efficient and informative. A flexible Bayesian trial design recently developed by FDA and NIH statisticians in response to an Ebola outbreak provides a case in point.
No hay comentarios:
Publicar un comentario